SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-20-000691
Filing Date
2020-08-18
Accepted
2020-08-18 16:35:59
Documents
2
Group Members
ORBIMED ISRAEL GP LTD.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 4 ss180003_sc13da.htm SC 13D/A 74229
2 JOINT FILING AGREEMENT ss180003_ex9901.htm EX-99.1 5447
  Complete submission text file 0000947871-20-000691.txt   81350
Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
Novus Therapeutics, Inc. (Subject) CIK: 0001404281 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88334 | Film No.: 201114163
SIC: 2834 Pharmaceutical Preparations

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 1022-4629
Business Address 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR HERZLIYA L3 46766 212-739-6400
OrbiMed Israel BioFund GP Limited Partnership (Filed by) CIK: 0001569821 (see all company filings)

IRS No.: 980697985 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13D/A